Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorROOS, I.
dc.contributor.authorLERAY, E.
dc.contributor.authorFRASCOLI, F.
dc.contributor.authorCASEY, R.
dc.contributor.authorBROWN, J.W.L.
dc.contributor.authorHORAKOVA, D.
dc.contributor.authorHAVRDOVA, E.K.
dc.contributor.authorDEBOUVERIE, M.
dc.contributor.authorTROJANO, M.
dc.contributor.authorPATTI, F.
dc.contributor.authorIZQUIERDO, G.
dc.contributor.authorEICHAU, S.
dc.contributor.authorEDAN, G.
dc.contributor.authorPRAT, A.
dc.contributor.authorGIRARD, M.
dc.contributor.authorDUQUETTE, P.
dc.contributor.authorONOFRJ, M.
dc.contributor.authorLUGARESI, A.
dc.contributor.authorGRAMMOND, P.
dc.contributor.authorCIRON, J.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurelie
dc.contributor.authorOZAKBAS, S.
dc.contributor.authorDE, Seze, J.
dc.contributor.authorLOUAPRE, C.
dc.contributor.authorZEPHIR, H.
dc.contributor.authorSA, M.J.
dc.contributor.authorSOLA, P.
dc.contributor.authorFERRARO, D.
dc.contributor.authorLABAUGE, P.
dc.contributor.authorDEFER, G.
dc.contributor.authorBERGAMASCHI, R.
dc.contributor.authorLEBRUN-FRENAY, C.
dc.contributor.authorBOZ, C.
dc.contributor.authorCARTECHINI, E.
dc.contributor.authorMOREAU, T.
dc.contributor.authorLAPLAUD, D.
dc.contributor.authorLECHNER-SCOTT, J.
dc.contributor.authorGRAND’MAISON, F.
dc.contributor.authorGERLACH, O.
dc.contributor.authorTERZI, M.
dc.contributor.authorGRANELLA, F.
dc.contributor.authorALROUGHANI, R.
dc.contributor.authorIULIANO, G.
dc.contributor.authorVAN PESCH, V.
dc.contributor.authorVAN WIJMEERSCH, B.
dc.contributor.authorSPITALERI, D.L.A.
dc.contributor.authorSOYSAL, A.
dc.contributor.authorBERGER, E.
dc.contributor.authorPREVOST, J.
dc.contributor.authorAGUERA-MORALES, E.
dc.contributor.authorMCCOMBE, P.
dc.contributor.authorCASTILLO TRIVINO, T.
dc.contributor.authorCLAVELOU, P.
dc.contributor.authorPELLETIER, J.
dc.contributor.authorTURKOGLU, R.
dc.contributor.authorSTANKOFF, B.
dc.contributor.authorGOUT, O.
dc.contributor.authorTHOUVENOT, E.
dc.contributor.authorHEINZLEF, O.
dc.contributor.authorSIDHOM, Y.
dc.contributor.authorGOUIDER, R.
dc.contributor.authorCSEPANY, T.
dc.contributor.authorBOURRE, B.
dc.contributor.authorAL KHEDR, A.
dc.contributor.authorCASEZ, O.
dc.contributor.authorCABRE, P.
dc.contributor.authorMONTCUQUET, A.
dc.contributor.authorWAHAB, A.
dc.contributor.authorCAMDESSANCHE, J.-P.
dc.contributor.authorMAUROUSSET, A.
dc.contributor.authorPATRY, I.
dc.contributor.authorHANKIEWICZ, K.
dc.contributor.authorPOTTIER, C.
dc.contributor.authorMAUBEUGE, N.
dc.contributor.authorLABEYRIE, C.
dc.contributor.authorNIFLE, C.
dc.contributor.authorCOLES, A.
dc.contributor.authorMALPAS, C.B.
dc.contributor.authorVUKUSIC, S.
dc.contributor.authorBUTZKUEVEN, H.
dc.contributor.authorKALINCIK, T.
dc.date.accessioned2022-04-22T08:50:54Z
dc.date.available2022-04-22T08:50:54Z
dc.date.issued2021-10
dc.identifier.issn1352-4585 1477-0970en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/139904
dc.description.abstractEnBackground: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) ⩾ 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2–34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3–36.8), females with EDSS < 6 and ARR ⩾ 1 44.8 weeks (95% CI = 24.5–65.1), and females with EDSS ⩾ 6 and ARR < 1 54.3 weeks (95% CI = 47.2–61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaquesen_US
dc.language.isoENen_US
dc.subject.enMultiple sclerosis
dc.subject.enNeurology
dc.subject.enObservational study
dc.subject.enTherapeutic lag
dc.title.enDeterminants of therapeutic lag in multiple sclerosis
dc.title.alternativeMult Scleren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/1352458520981300en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33423618en_US
bordeaux.journalMultiple Sclerosis Journalen_US
bordeaux.page1838-1851en_US
bordeaux.volume27en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue12en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Multiple%20Sclerosis%20Journal&amp;rft.date=2021-10&amp;rft.volume=27&amp;rft.issue=12&amp;rft.spage=1838-1851&amp;rft.epage=1838-1851&amp;rft.eissn=1352-4585%201477-0970&amp;rft.issn=1352-4585%201477-0970&amp;rft.au=ROOS,%20I.&amp;LERAY,%20E.&amp;FRASCOLI,%20F.&amp;CASEY,%20R.&amp;BROWN,%20J.W.L.&amp;rft.genre=article


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record